|
Study of Daclizumab in Patients with Chronic, Persistent Asthma Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Study of Daclizumab in Patients with Chronic, Persistent Asthma conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Study of Daclizumab in Patients with Chronic, Persistent Asthma Clinical research trials and Study of Daclizumab in Patients with Chronic, Persistent Asthma medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Study of Daclizumab in Patients with Chronic, Persistent Asthma. Study of Daclizumab in Patients with Chronic, Persistent Asthma Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Study of Daclizumab in Patients with Chronic, Persistent Asthma clinical trial. Participants frequently obtain the most expert healthcare available for their Study of Daclizumab in Patients with Chronic, Persistent Asthma condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Daclizumab in Patients with Chronic, Persistent Asthma  Study of Daclizumab in Patients with Chronic, Persistent Asthma
Study of Daclizumab in Patients with Chronic, Persistent Asthma
For Condition: Asthma
Status: No longer recruiting
Sponsor(s): Protein Design Labs ,
Synopsis: The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site over a 10-month period. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/70 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - History of asthma for 6 or more months - History of chronic persistent asthma requiring daily high dose inhaled corticosteroid for 3 or more months prior to enrollment Exclusion Criteria: - Patients with 10 or more pack years of smoking history or smoking within 12 months of study enrollment - No significant disease other than asthma
Total Enrollment: 120
Location and Contact Information:
Valley Clinical Research Center
Easton, Pennsylvania, 18045
United States
Southern California Research
Mission Viejo, California, 92691
United States
Allergy and Respiratory Care Center
Milwaukee, Wisconsin, 53209
United States
Institute of Health Care Assessment, Inc.
San Diego, California, 92120
United States
Medical Research Associates
Long Beach, California, 90806
United States
Clinical Reserch Centers of Colorado
Denver, Colorado, 80230
United States
Rx Research
Woodstock, Georgia, 30188
United States
Asthma and Allergy Center of Chicago, S.C.
River Forest, Illinois, 60305
United States
Allergy, Asthma, and Dermatology Research Center, LLC
Lake Oswego, Oregon, 97035
United States
University of Wisconsin Medical School
Madison, Wisconsin, 53792
United States
National Jewish Medical and Research Center
Denver, Colorado, 80206
United States
Clinical Research Institute
Minneapolis, Minnesota, 55402
United States
Bensch Research Associates
Stockton, California, 95207
United States
Florida Center for Allergy and Asthma Reserch
Miami, Florida, 33176
United States
ICSL Clinical Studies
Bloomington, Illinois, 61704
United States
New England Clinical Studies
North Dartmouth, Massachusetts, 02747
United States
Pharmaceutical Research and Consulting, Inc.
Dallas, Texas, 75231
United States
Princeton Center for Clinical Research
Princeton, New Jersey, 08540
United States
Additional Information:
Study ID Numbers: DAC-1003;
Study Start Date: September 2001
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00028288
Other Asthma Studies:
1. Early Risk Predictors For Chronic Pulmonary Disease
2. Epidemiology of Airway Responsiveness
3. Long-term Safety Performance of Fexofenadine in Asthma
4. Study of Daclizumab in Patients with Chronic, Persistent Asthma
5. Genetics of Asthma and Bronchial Hyperresponsiveness
Related Studies:
Other Asthma Clinical Trials
Other Texas Clinical Trials
Other Dallas Clinical Trials
Study of Daclizumab in Patients with Chronic, Persistent Asthma
|
|
|
|
|
|
|
|
